Molecular genotyping is essential for management of patients newly diagnosed with
advanced non-small cell lung cancer (NSCLC). Plasma circulating tumor DNA (ctDNA) …

Background It is difficult to identify tumor driving genes in advanced non-small cell lung
cancer (NSCLC) patients especially for those who were unable to obtain cancer tissue …

Background Circulating tumor DNA (ctDNA) testing represents a powerful tool to detect gene
alterations in patients. However, differences in mutation detected by ctDNA related to …

Background & aims: Targeted therapy has transformed the care of lung cancer patients by
incorporating tumour genotyping into therapeutic decision making. Improvements in …

Despite the overwhelming enthusiasm for the promises of immunotherapy in treating lung
cancer, tumor genetic biomarker testing for other targeted therapies remains a central tenet …

e21202 Background: Circulating tumor DNA (ctDNA) encompasses spatial and temporal
heterogeneity, tumor evolution, and is ideal for repeat sampling and predictive therapeutic …

Introduction: Liquid biopsy methodology has long been utilized in management of patients
with advanced lung cancer. The approach found its use in testing for a presence of somatic …

According to current practice guidelines, all patients with advanced non-small cell lung
cancer (NSCLC) should undergo predictive biomarker testing. For squamous cell carcinoma …

Results Median follow-up was 38 months. All patients with detectable ctDNA during post-
treatment surveillance (n= 22) developed disease progression (P< 0.00001) and had worse …

9101 Background: Approximately 20% of tumor biopsies from patients with advanced-stage
lung adenocarcinomas yield insufficient tissue for successful molecular subtyping. In this …